This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Initiating Early Control of Migraine Pain and Asso...
Clinical trial

Initiating Early Control of Migraine Pain and Associated Symptoms (INTERCEPT)

Read time: 3 mins
Last updated:8th Oct 2019
Identifier: NCT04163185

AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This study is designed to evaluate the efficacy and safety of AXS-07 compared to placebo.

This is a randomized, double-blind, single-dose, placebo-controlled trial. Subjects who successfully complete the screening period and continue to meet all entry criteria will be randomly assigned to take one dose of either AXS-07 or placebo upon the earliest onset of migraine pain.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults
Actual Study Start Date: October 8, 2019
Estimated Primary Completion Date: March 2020
Estimated Study Completion Date: March 2020

Arms:
- Experimental:
AXS-07
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2019-11-14
Study type(s) Interventional
Expected enrolment 300
Study start date 2019-10-08
Estimated primary completion date 2020-03-01

View full details